Is the FDA Changing Its Tune on Evoke Pharma?
Evoke Pharma shares saw a handy gain on Wednesday following news of a positive meeting with the FDA over Gimoti.
Evoke Pharma shares saw a handy gain on Wednesday following news of a positive meeting with the FDA over Gimoti.
Shares of Retrophin climbed early on Wednesday following positive top-line news from its mid-stage trial for the treatment of focal segmental glomerulosclerosis.
Tonix Pharmaceuticals was the disaster of the day on Tuesday after the company announced that it will stop development of its fibromyalgia treatment after it failed in a late-stage trial.
It is not uncommon for an acquirer to see its shares drop on news when it makes an acquisition. Still, when investors see both companies rise on a merger announcement then they automatically assume…
What most investors are looking for is a solid solution in what is a confusing market. So we have compiled a list of a few biotech companies that fit the bill, and analysts are…
This year marks a watershed in state legalization of marijuana, triggered by a change in social norms, the taxation yield promise, and the fact that, in many states, marijuana is already approved for medical…
One election year hot-button issue that is back on the table is the ongoing fight over drug prices. But the public has been debating drug prices for years now — long before the EpiPen…
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.
If the independent research firm Argus is correct, then Boston Scientific shareholders could see an upside of roughly 40% from the current price level.
Shares of Cynapsus Therapeutics more than doubled on Thursday after it was announced that Sunovion Pharmaceuticals would be acquiring the company.
According to The Wall Street Journal, blood testing company Theranos and its CEO Elizabeth Holmes have suffered a new, major setback.
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
Shares of Array BioPharma saw a handy gain in Tuesdays session following the announcement of mid-stage results from its cardiomyopathy trial.
Shares of Rigel Pharmaceuticals skyrocketed early on Tuesday after the company reported incredibly positive results from its late-stage blood platelet clinical trial.
St. Jude Medical has issued a press release aimed at responding to points in the Muddy Waters report, and a Credit Suisse research report has dispelled some of the concerns.